Hormonal agents used in lowering lipoprotein(a)

This publication has 21 references indexed in Scilit:

• Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations.
  Journal of Clinical Investigation, 1992
• Risks and Benefits of Replacement Estrogen
  Annual Review of Medicine, 1992
• Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid
  Atherosclerosis, 1992
• Lipoprotein (a) concentrations in postmenopausal women taking norethisterone.
  BMJ, 1991
• Estrogen replacement therapy for reduction of cardiovascular risk in women
  Current Opinion in Lipidology, 1991
• Effects of estrogen and progesterone on plasma lipoproteins and experimental atherosclerosis in the baboon (Papio sp.).
  Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991
• Gynecologic consequences of long-term, unopposed estrogen replacement therapy
  Maturitas, 1988
• Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography.
  Circulation, 1986
• Quantitation, isolation, and characterization of human lipoprotein (a)
  Published by Elsevier ,1986
• Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1984